{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:06:28Z","timestamp":1758845188843,"version":"3.44.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hemodialysis is an important life-sustaining treatment for patients with end-stage renal failure (ESRF), but its ultrafiltration process may induce hypoalbuminemia and compromise systemic immune competence. In Ulcerative colitis (UC), immune dysregulation underlies chronic inflammation. Vedolizumab (VDZ), a humanized monoclonal antibody selectively targeting the \u03b14\u03b27 integrin expressed on gut-homing lymphocytes, demonstrates efficacy in moderate-to-severe UC. However, its pharmacokinetic profile in hemodialysis-dependent patients remains poorly defined due to limited data in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 50-year-old male with ESRF secondary to renal allograft failure (2012) received maintenance thrice-weekly hemodialysis. In February 2022, he developed mucoid and bloody purulent stools and was diagnosed with UC. Initial therapy with oral mesalazine (4\u202fg daily) failed to control symptoms, resulting in clinical deterioration. Subsequently, VDZ was initiated at a standard induction regimen: 300\u202fmg intravenous infusions at weeks 0, 2, 6, followed by maintenance dosing every 8\u202fweeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention and outcome<\/jats:title><jats:p>Clinical remission with complete mucosal healing (Mayo endoscopic score 0) was achieved by week 22. Post-dialysis trough serum VDZ concentration measured 13.35\u202f\u03bcg\/mL, with no detectable anti-drug antibodies. Renal function remained stable throughout (estimated glomerular filtration rate [eGFR] 3.45\u202fmL\/min\/1.73m<jats:sup>2<\/jats:sup>), confirming therapeutic efficacy without exacerbation of uraemic complications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1616425","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:29:54Z","timestamp":1758778194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis on hemodialysis for end-stage renal failure: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Zezheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.kint.2019.01.017","article-title":"Dialysis initiation, modality choice, access, and prescription: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"96","author":"Chan","year":"2019","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2012.04.019","article-title":"Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report","volume":"60","author":"Lacson","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet (lond Engl)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.3748\/wjg.v26.i28.3998","article-title":"Secondary causes of inflammatory bowel diseases","volume":"26","author":"Ghouri","year":"2020","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17235\/reed.2020.7361\/2020","article-title":"Inflammatory bowel disease and solid organ transplantation","volume":"113","author":"Mart\u00ednez Montiel","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"24709","DOI":"10.18632\/aging.202345","article-title":"Post-transplant colitis after kidney transplantation: clinical, endoscopic and histological features","volume":"12","author":"Gioco","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.6002\/ect.2023.0196","article-title":"Inflammatory bowel diseases and kidney transplantation: a narrative review of clinical management approaches","volume":"21","author":"Alalawi","year":"2023","journal-title":"Exp Clin Transplant: Off J Middle East Soc Organ Transplant"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ibd\/izad108","article-title":"Safety of biologic and small molecule therapy for inflammatory bowel disease among solid organ transplant recipients: systematic review and meta-analysis","volume":"30","author":"Taneja","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11255-013-0542-8","article-title":"Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients","volume":"46","author":"Dumea","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ajhp\/zxaa089","article-title":"Procalcitonin in special patient populations: guidance for antimicrobial therapy","volume":"77","author":"Smith","year":"2020","journal-title":"Am J Health-syst Pharm: AJHP: Off J Am Soc Health-syst Pharm"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14737159.2018.1407244","article-title":"Novel applications for serum procalcitonin testing in clinical practice","volume":"18","author":"Choi","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/phar.2112","article-title":"Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature","volume":"38","author":"Covington","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s15006-021-9959-7","article-title":"Procalcitonin (PCT)","volume":"163","author":"Horns","year":"2021","journal-title":"MMW Fortschr Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5414\/cpp48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1616425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:29:55Z","timestamp":1758778195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1616425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":15,"alternative-id":["10.3389\/fmed.2025.1616425"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1616425","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1616425"}}